Cargando…

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971277/ https://www.ncbi.nlm.nih.gov/pubmed/31959756 http://dx.doi.org/10.1038/s41467-019-14111-3

Ejemplares similares

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: Griguolo, G., et al.
Publicado: (2021)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2021)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
por: Pernas, Sonia, et al.
Publicado: (2021)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2021)

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
por: Schettini, F., et al.
Publicado: (2023)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
por: Brasó-Maristany, Fara, et al.
Publicado: (2021)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
por: Schettini, F., et al.
Publicado: (2021)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

Quantification of HER family receptors in breast cancer
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f63h003q3d7jl0iparvok2klg5